The opportunity for increased collaboration between electronics and biology has changed the medical world creating a completely new field of medicine. Electronic devices, such as pacemakers, have been revolutionizing medicine over the past several generations. These electronic medical devices have traditionally been used in a mechanical fashion like assisting in the pumping of the heart.

However, new classes of medical devices, often referred to as “Electroceuticals,” are rapidly changing the way some rather serious diseases may be treated. This medical revolution stems from an emerging field of medicine called Bioelectronic Medicine.  In many ways, this new field of medicine isnot only the result of large advancements in electrical engineering and biophysics, but also a direct response to a drug industry continuing to see drug development costs rise, prices increase and persisting serious side effects.

Bioelectronic medicine seeks to address these issues by creating a new class of medicines costing less to develop, be simply modified to treat other diseases, further reduce costs by economies of scale and minimize side effects.

In the next decade, it may become possible to restore vision or reverse the effects of spinal cord injury as well as other diseases such as heart, kidney or liver failure; or create a lab-on-a-chip to allow medical diagnoses without a clinic, study diseases or instantaneous biological agent detection.


When thinking of biotech companies, we often think of Big Pharma and the research and development that created classic devices such as defibrillators, single modality (X Rays), and magnetic resonance imaging (MRI). With advances in biotechnology it is important to keep an eye on the smaller companies like Endonovo Therapeutics (ENDV).

ENDV’s diverse team contains experts in the field of biophysics, medical research, clinical and surgical research, corporate development, and banking and corporate finance. This multidisciplinary approach to biotechnology research and development is positioning them as a leader in bioelectronic medicine.  

Most recently, ENDV announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in the treatment of critical limb ischemia (CLI). “Critical Limb Ischemia is found in about 12% of the U.S. adult population and its progression can lead to the amputation of limbs with more than 60% of patients with CLI having died at 5 years.” stated ENDV Chairman and CEO, Alan Collier.

CLI is a severe condition of peripheral artery disease (PAD), which results from a progressive thickening of an arteries lining, caused by a buildup of plaque. This buildup of plaque, also known as atherosclerosis, narrows or blocks blood flow, reducing circulation of blood to the legs, feet or hands. This reduced circulation causes necrosis and extreme pain in limbs and often results in an amputation.

Endonovo’s Immunotronics™ technology is dedicated to treating patients with life-threatening inflammatory conditions in tissues and vital organs by using proprietary non-invasive electroceutical devices. The Company’s non-invasive platform is based on the stimulation of magnetically-induced electrical field pathways in cells that target the disruption of inflammation and cell death.

ENDV’s technology has already shown great promise in bone regeneration and reducing inflammation in a pharmaceutical industry “gold standard” model of inflammation. The Company is now targeting the attenuation of the inflammatory response in specific organs in order to treat life threatening diseases and conditions, such as heart, kidney and liver disease.

The pre-clinical study will evaluate the effect of the Company’s non-invasive electroceutical technology on limb function, ischemia damage and blood flow, including the formation of new blood vessels (angiogenesis). The study is part of the Company’s strategy to develop a pipeline of non-invasive electroceutical treatments for vascular diseases, ischemia/reperfusion injuries and ischemia wounds.

Keep your eyes open for the results of ENDV’s pre-clinical study as they position themselves for exponential growth for continued success.


Insys Therapeutics (INSY) Interim CEO and Chief Medical Officer Dr. Santosh Vetticaden resigned on April 28th, Saeed Motahari took over as President & CEO. They announced their first quarter financial results this morning. Insys Therapeutics (INSY +9.8%) Q1 results: Revenues: $36M (-40.4%); Operating Loss: ($12.3M); Net Loss: ($6.5M); Loss Per Share: ($0.09); Quick Assets: $155.3M (-15.1%).

Portola Pharmaceuticals Inc. (PTLA) today announced that clinical results from the Phase 2 study of cerdulatinib in patients with relapsed/refractory b-cell malignancies will be shared in an oral presentation at the International Conference on Malignant Lymphoma (ICML). This conference will take place June 14-17 in Lugano, Switzerland.  

AMRI is a global contract research and manufacturing organization that has been working with the life sciences industry to improve patient outcomes and the quality of life for more than two decades. Earlier this month, they announced a 5-year federal contract award with the National Institute of Health (NIH) for drug substance and manufacturing services.

Corcept Therapeutics Inc. (CORT) has increased its 2017 revenue guidance yet again. The Company now expects 2017 revenue to range between $125 million and $135 million.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.

For Full Legal Disclaimer Click Here.

Media Contact
Company Name: Microcap Speculators
Contact Person: Media Manager
Phone: 1-702-720-6310
Country: United States